Sanofi Pasteur's dengue vaccine works in three out of four serotypes
This article was originally published in Scrip
Executive Summary
Sanofi Pasteur has reported an early Phase III data analysis which confirms the efficacy of its tetravalent dengue vaccine candidate against three of the four virus serotypes circulating in Thailand. The company said that "analyses are ongoing to understand the lack of protection for the fourth serotype in the particular epidemiological context of Thailand".